250 related articles for article (PubMed ID: 30016177)
1. Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
Dantal J; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; Del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra A; Hofbauer GFL; Kamar N; Pouteil-Noble C; Kanitakis J; Roux A; Decullier E; Euvrard S;
J Clin Oncol; 2018 Sep; 36(25):2612-2620. PubMed ID: 30016177
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
Euvrard S; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra AL; Hofbauer GF; Pouteil-Noble C; Campistol JM; Kanitakis J; Roux AS; Decullier E; Dantal J;
N Engl J Med; 2012 Jul; 367(4):329-39. PubMed ID: 22830463
[TBL] [Abstract][Full Text] [Related]
3. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
[No Abstract] [Full Text] [Related]
4. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.
van den Akker JM; Wetzels JF; Hoitsma AJ
Kidney Int; 2006 Oct; 70(7):1355-7. PubMed ID: 16912706
[TBL] [Abstract][Full Text] [Related]
5. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus.
Hoogendijk-van den Akker JM; Harden PN; Hoitsma AJ; Proby CM; Wolterbeek R; Bouwes Bavinck JN; de Fijter JW
J Clin Oncol; 2013 Apr; 31(10):1317-23. PubMed ID: 23358973
[TBL] [Abstract][Full Text] [Related]
6. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
[TBL] [Abstract][Full Text] [Related]
7. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
8. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
Alberú J; Pascoe MD; Campistol JM; Schena FP; Rial Mdel C; Polinsky M; Neylan JF; Korth-Bradley J; Goldberg-Alberts R; Maller ES;
Transplantation; 2011 Aug; 92(3):303-10. PubMed ID: 21792049
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.
Campbell SB; Walker R; Tai SS; Jiang Q; Russ GR
Am J Transplant; 2012 May; 12(5):1146-56. PubMed ID: 22420843
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus and non-melanoma skin cancer prevention after kidney transplantation: a meta-analysis.
Gu YH; Du JX; Ma ML
Asian Pac J Cancer Prev; 2012; 13(9):4335-9. PubMed ID: 23167339
[TBL] [Abstract][Full Text] [Related]
11. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus and skin-cancer prevention in kidney transplantation.
Smak Gregoor PJ
N Engl J Med; 2012 Oct; 367(16):1565; author reply 1565-6. PubMed ID: 23075186
[No Abstract] [Full Text] [Related]
13. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
14. Use of sirolimus as an adjuvant therapy for kidney transplant recipients with high-risk cutaneous squamous cell carcinomas: a prospective non-randomized controlled study.
Fázio MR; Cristelli MP; Tomimori J; Koga CE; Ogawa MM; Beneventi GT; Tedesco-Silva H; Medina-Pestana J
J Bras Nefrol; 2023; 45(4):480-487. PubMed ID: 37565728
[TBL] [Abstract][Full Text] [Related]
15. Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients.
Euvrard S; Boissonnat P; Roussoulières A; Kanitakis J; Decullier E; Claudy A; Sebbag L
Transpl Int; 2010 Aug; 23(8):855-7. PubMed ID: 19951373
[No Abstract] [Full Text] [Related]
16. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
17. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
Leblanc KG; Hughes MP; Sheehan DJ
Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment.
Kim C; Cheng J; Colegio OR
Semin Oncol; 2016 Jun; 43(3):390-4. PubMed ID: 27178693
[TBL] [Abstract][Full Text] [Related]
19. Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
Rival-Tringali AL; Euvrard S; Decullier E; Claudy A; Faure M; Kanitakis J
Anticancer Res; 2009 Jun; 29(6):1927-32. PubMed ID: 19528449
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
